Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail - unveiling that more than half could be targeted by drugs currently in trials for other cancer types.
This research, published today in Nature Genetics, could help stratify oesophageal cancer patients to give them more personalised therapies. This could provide options not currently available to patients beyond standard chemotherapy, radiotherapy or surgery.
Cancer Research UK researchers at the University of Cambridge used whole genome sequencing and whole exome sequencing* to map mutations in OAC, the main subtype of oesophageal cancer in England.
In the study, driver mutations for OAC were found in 99% of patients and more than 50% were sensitive to drugs (CDK4/6 inhibitors) already in clinical trials for breast cancer. This means phase II/III clinical trials to treat oesophageal cancer could be feasible in one to two years.
Interestingly, women were found to have more KRAS** mutations than men. These mutations are often seen in other cancer types, but are rarely found in oesophageal cancer. This could indicate a different sub-type of the disease in women and suggest they may have a different prognosis or be eligible for other treatments.
Professor Rebecca Fitzgerald, Cancer Research UK funded scientist and lead researcher at the MRC Cancer Unit, said: "This research could completely shift the paradigm from giving oesophageal cancer patients the same chemotherapy that we know doesn't always work, to more targeted treatments based on individual characteristics of a patient's cancer.
"We are now designing clinical trials that provide real-time analysis of patients' genes to offer patients the best treatment based on their own genome.
"This research could also provide better options for older patients, who are more likely to develop oesophageal cancer, and who are often not fit enough for current treatment options."
Only around 12% of patients survive oesophageal cancer for 10 years or more***. This is partly due to late diagnosis, as symptoms often do not present until the cancer is advanced, and partly due to limited treatment options. Scientists have found that more people are developing OAC in several countries in Western Europe, including the UK - risk factors include obesity and smoking****.
Professor Karen Vousden, Cancer Research UK's chief scientist, said: "Research like this is crucial to improve treatment options and survival for patients facing a hard-to-treat cancer, such as oesophageal cancer.
"Understanding which mutations are causing the disease could lead to targeted treatments and earlier detection. This is something that would never have been possible without huge advances in technology."
Cancer Research UK is committed to funding more research on hard to treat cancers like oesophageal cancer, increasing spending from £5 million four years ago, to £16 million this year*****. In the UK, oesophageal cancer is the 13th most common cancer and the seventh most common cause of cancer death in the UK******.
For media enquiries contact Angharad Kolator Baldwin in the Cancer Research UK press office on 020 3469 8456 or, out of hours, on 07050 264 059.
Notes to editor:
Cancer Research UK's International Symposium on Oesophageal Cancer will take place in London 29-30 April 2019, Professor Rebecca Fitzgerald is the scientific lead for this event.
Frankell, A., et al. The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic. Nature Genetics
* Whole genome sequencing is a method to determine the order of nucleotides in an organism's DNA, including chromosomal and mitochondrial DNA. Whole exome sequencing is a technique to sequence all the protein-coding genes in an individual's genome.
** KRAS is a gene involved in cell signalling and when functioning normally controls cell proliferation.
OAC incidence is highest in those aged 85-89 (2013-15). Source: https:/
*** People diagnosed with oesophageal cancer in England and Wales (2010-11). Source: https:/
***** Cancer Research UK annual report (2017-2018).
****** accounting for 5% of all cancer deaths (2016). Source: https:/
This research was conducted as part of a multicentre consortium including the International Cancer Genome Consortium (ICGC), and the Oesophageal Cancer Clinical and Molecular Stratification study (OCCAMS) group. The project was funded by Cancer Research UK.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.